title: Use of gemcitabine-platinum in Indian patients with advanced gall bladder cancer.
abstract: BACKGROUND
  Gemcitabine-platinum (Gem-P) is the current standard for patients with advanced gall bladder cancer.
  
  
  METHODS
  This is retrospective analysis of a prospectively maintained database of 210 patients with advanced gall bladder cancer treated with Gem-P between January 2012 and September 2013.
  
  
  RESULTS
  Median age was 53 years, 65.2% females. In total,158 patients had metastatic and 52 had locoregional disease. Median number of cycles was 5 (1-12). At a median follow-up of 10 months, median overall survival/progression-free survival was 10/5 months, respectively. On multivariate analysis, patients who underwent prior surgery for primary and locoregional disease had a significantly better progression-free survival and those with locoregional disease had a significantly better overall survival. A total of 45.7% received second-line chemotherapy.
  
  
  CONCLUSIONS
  Use of Gem-P in Indian patients leads to slightly worse outcomes suggesting an aggressive biology.
authors.affiliation: Department of Medical Oncology, Tata Memorial Centre, Parel, Mumbai, India.
authors.forename: Bhawna
authors.initials: B
authors.lastname: Sirohi
authors.forename: Sameer
authors.initials: S
authors.lastname: Rastogi
authors.forename: Ashish
authors.initials: A
authors.lastname: Singh
authors.forename: Vipul
authors.initials: V
authors.lastname: Sheth
authors.forename: Shaheenah
authors.initials: S
authors.lastname: Dawood
authors.forename: Sanjay
authors.initials: S
authors.lastname: Talole
authors.forename: Mukta
authors.initials: M
authors.lastname: Ramadwar
authors.forename: Suyash
authors.initials: S
authors.lastname: Kulkarni
authors.forename: Shailesh V
authors.initials: SV
authors.lastname: Shrikhande
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D002945:Cisplatin / Q000008:administration & dosage; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D018572:Disease-Free Survival; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives; D005706:Gallbladder Neoplasms / Q000188:drug therapy* / Q000473:pathology* / Q000601:surgery; D006801:Humans; D007194:India; D057148:Insecticide-Treated Bednets; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin; D010166:Palliative Care; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome; D000093542:Gemcitabine
chemical_list: D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D003841:Deoxycytidine; D002945:Cisplatin; D005472:Fluorouracil; D002166:Camptothecin; D000093542:Gemcitabine
keywords: advanced; chemotherapy; gall bladder cancer; gemcitabine–platinum